ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator's choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.

被引：0

作者：

Olawaiye, Alexander

Monk, Bradley J.

Herzog, Thomas J.

Copeland, Larry J.

Coleman, Robert L.

Moore, Kathleen N.

Randall, Leslie M.

Slomovitz, Brian M.

O'Malley, David M.

Eskander, Ramez Nassef

Pothuri, Bhavana

Van Gorp, Toon

Pignata, Sandro

Nicum, Shibani

Tudor, Iulia Cristina

Nguyen, Dorothy D.

Lorusso, Domenica

机构：

[1] Univ Pittsburgh, Pittsburgh, PA USA

[2] Creighton Univ Sch Med, Univ Arizona Coll Med, GOG Fdn, Phoenix, AZ USA

[3] Univ Cincinnati Canc Inst, Cincinnati, OH USA

[4] Ohio State Univ, James Canc Ctr, Columbus, OH USA

[5] US Oncol Res, Spring, TX USA

[6] Univ Oklahoma HSC, Stephenson Canc Ctr, Oklahoma City, OK USA

[7] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA

[8] Florida Int Univ, Mt Sinai Med Ctr, Miami Beach, FL USA

[9] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH USA

[10] Moores Canc Ctr, La Jolla, CA USA

[11] NYU Grossman Sch Med, Perlmutter Canc Ctr, NYU Langone Hlth, Ney York, NY USA

[12] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

[13] Ist Nazl Tumori Napoli, Naples, Italy

[14] Univ Coll London Canc Inst, London, England

[15] Corcept Therapeut, Menlo Pk, CA USA

[16] Catholic Univ, IRCCS, Sacred Heart & Fondazione Policlinico Gemelli, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS5620

引用

页数：1

共 50 条

[31] Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Backes, Floor
Wei, Lai
Copeland, Larry
Cohn, David
Fowler, Jeffrey
Bixel, Kristin
Cosgrove, Casey
Hays, John
Myers, Molly
Dodd, Kelly
O'Malley, David
GYNECOLOGIC ONCOLOGY, 2021, 162 : S68 - S69
[32] Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer
Yoshino, Kiyoshi
Kamiura, Shoji
Ogawa, Haruki
Tokuhira, Atsushi
Takemura, Masahiko
Sawada, Kenjiro
Ueda, Yutaka
Mabuchi, Seiji
Fujita, Masami
Tsutsui, Tateki
Kimura, Tadashi
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Concin, Nicole
Braicu, Ioana
Combe, Pierre
Ray-Coquard, Isabelle Laure
Joly, Florence
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34] SAFETY AND EFFICACY OF NIRAPARIB IN PATIENTS WITH ADVANCED, RELAPSED, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (QUADRA)
Moore, K.
Rimel, B. J.
Achour, H.
Naumov, G.
Agarwal, S.
Balser, J.
Monk, B. J.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 784 - 784
[35] PHASE II TRIAL EVALUATING EFFICACY AND SAFETY OF STANDARD OF CARE WITH OR WITHOUT BEVACIZUMAB IN PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
Nishikawa, N.
Shoji, T.
Enomoto, T.
Abe, M.
Okamoto, A.
Saito, T.
Oishi, T.
Nagase, S.
Mori, M.
Inokuchi, Y.
Kamiura, S. K.
Sugiyama, T.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A10 - A11
[36] Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.
Ben Liao, John
Swensen, Ron E.
Reichow, Jessica
Ovenell, Kelsie J.
Childs, Jennifer
Higgins, Doreen
Buening, Barbara
Goff, Barbara Ann
Morishima, Chihiro
Disis, Mary L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[37] MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression
Moore, Kathleen
Konecny, Gottfried
Martin, Lainie
Floquet, Anne
O'Malley, David
Colombo, Nicoletta
Mantia-Smaldone, Gina
Banerjee, Susana
Gilbert, Lucy
de Gregorio, Nikolaus
Tromp, Jacqueline
Wang, Jiuzhou
Esteves, Brooke
Method, Michael
Van Gorp, Toon
GYNECOLOGIC ONCOLOGY, 2022, 166 : S156 - S157
[38] Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Colombo, Nicoletta
Van Gorp, Toon
Matulonis, Ursula A.
Oaknin, Ana
Grisham, Rachel N.
Fleming, Gini F.
Olawaiye, Alexander
Pashova, Hristina I.
Nguyen, Dorothy D.
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[39] Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Kelly, Michael G.
Mor, Gil
Husband, Alan
O'Malley, David M.
Baker, Lisa
Azodi, Masoud
Schwartz, Peter E.
Rutherford, Thomas J.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (04) : 633 - 639
[40] Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Moore, Kathleen N.
McMeekin, D. Scott
Hamilton, Erika Paige
Strickland, Donald K.
Jones, Suzanne Fields
Stults, Dawn Michelle
Laing, Naomi
Spigel, David R.
Burris, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →